THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

(RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled ...

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...

Repatha is an effective medication that can lower LDL cholesterol and significantly reduce the risk of heart attacks and strokes. Like most drugs, Repatha can cause side effects. However long-term ...

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...